4D Molecular Therapeutics, Inc.
FDMT
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial foā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$10.50
Price-3.85%
-$0.42
1Y
Price
Market Cap
$490.343m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-396373.3%
EBITDA Margin-364386.7%
Net Profit Margin-289180.0%
Free Cash Flow MarginRevenue
$33k
-10.8%
1y CAGR+150.6%
3y CAGR+92.3%
5y CAGREarnings
-$196.144m
-21.9%
1y CAGR-27.1%
3y CAGR-32.3%
5y CAGREPS
-$3.53
-18.5%
1y CAGR-5.5%
3y CAGR-10.9%
5y CAGRBook Value
$420.890m
$473.637m
Assets$52.747m
Liabilities$23.077m
DebtDebt to Assets
4.9%
-0.1x
Debt to EBITDAFree Cash Flow
-$166.279m
-20.2%
1y CAGR-25.4%
3y CAGR-25.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company